Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.43 |
| ▸ | KDM1A | O60341 | 6/20 | 0.38 |
| ▸ | HCK | P08631 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202007 | 0.88 | DGAT2 (0.37) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL13007256 | 0.87 | DGAT2 (0.39) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3767967 | 0.83 | HDAC6 (0.59) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15906821 | 0.83 | HDAC6 (0.59) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8203628 | 0.82 | KDM1A (0.42) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3778383 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8194298 | 0.79 | DGAT2 (0.35) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8203640 | 0.79 | DGAT2 (0.39) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8195710 | 0.76 | HDAC6 (0.40) | HDAC6HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL16517896 | 0.76 | HDAC6 (0.52) | HDAC6HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| EP-2077999-B1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-12-16 | — | — | US | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | H1-2, HDAC1, H1-0 | HDAC6 23/4885HDAC1 2/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.